Blood vessel inhibitors have been pursued as anticancer agents, but in low doses they may actually promote blood-vessel formation and tumour growth in mice. The results, published online in Nature Medicine, call for a reassessment of these inhibitors as anticancer agents, with implications for their potential use in humans.
Certain inhibitors of integrins -- cell surface receptors that define cellular shape, mobility, and regulate the cell cycle -- have entered clinical trials as agents for cancer treatment, owing to their ability to prevent angiogenesis (blood-vessel growth), but their success has been limited. Andrew Reynolds, Kairbaan Hodivala-Dilke and their colleagues show that low concentrations of integrin inhibitors can paradoxically stimulate tumour growth and tumour angiogenesis by altering the trafficking of one specific integrin and of a well known proangiogenic molecule.
Andrew Reynolds (Institute of Cancer Research, London, UK)
Kairbaan Hodivala-Dilke (Cancer Research UK, London, UK)
Abstract available online.
(C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza